GERN - Geron Corporation
3.96 0.00 (0.00%)
After hours: 6:25PM EDT
| Previous Close | 3.86 |
| Open | 3.87 |
| Bid | 3.90 x 3100 |
| Ask | 3.93 x 1000 |
| Day's Range | 3.80 - 3.96 |
| 52 Week Range | 1.74 - 6.68 |
| Volume | 2,216,855 |
| Avg. Volume | 4,516,984 |
| Market Cap | 727.143M |
| Beta | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.75 |
Yahoo Finance Video•16 days agoNYSE trader: Expect volatility around Tesla earnings and the earnings call will be interesting
Matthew Cheslock joins Yahoo Finance from the floor of the New York Stock Exchange to discuss the latest market moves.
- Motley Fool•11 hours ago
Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
- GlobeNewswire•2 days ago
Recent Analysis Shows Automatic Data Processing, Denbury Resources, ITT, Cardinal Health, Geron, and The Hackett Group Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Automatic ...
- Zacks•3 days ago
Implied Volatility Surging for Geron (GERN) Stock Options
Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•3 days ago
Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / U.S. equities plunged on Friday as rising currency crisis in Turkey fueled a global market pullback. The Turkish lira is down 20 percent this week, slumping ...
- Motley Fool•10 days ago
3 Reasons Geron Corporation Stock Could Be a Big Winner
The biotech's day of reckoning is close at hand.
- Zacks•15 days ago
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
- Benzinga•15 days ago
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of GERN earnings conference call or presentation 31-Jul-18 8:30pm GMT
Q2 2018 Geron Corp Earnings Call
- Associated Press•16 days ago
Geron: 2Q Earnings Snapshot
On a per-share basis, the Menlo Park, California-based company said it had a loss of 4 cents. The drugmaker posted revenue of $208,000 in the period. In the final minutes of trading on Tuesday, the company's ...
- GlobeNewswire•16 days ago
Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
MENLO PARK, Calif., July 31, 2018-- Geron Corporation today reported financial results for the three and six months ended June 30, 2018.. Second Quarter and Year to Date 2018 Results. For the second quarter ...
- ACCESSWIRE•16 days ago
Geron Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Geron Corporation (NASDAQ: GERN ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 31, 2018 at 4:30 PM Eastern Time. To ...
- ACCESSWIRE•17 days ago
Two Biotech Firms, Who's Stock Could Skyrocket
HENDERSON NV / ACCESSWIRE / July 30, 2018 / In recent weeks, several biotech companies have released positive news around Q2 financials, and several are set to release updates this week. Making it a sector ...
- Motley Fool•21 days ago
3 Stocks That Could Double Your Money
Find out why these three biotech stocks could be huge winners.
- GlobeNewswire•23 days ago
Geron to Announce Second Quarter 2018 Financial Results on July 31, 2018
Geron Corporation (GERN) today announced that it will release its second quarter 2018 financial results after the market closes on Tuesday, July 31, 2018. Geron will host a conference call to discuss the second quarter results and recent events at 4:30 p.m. ET the same day. Geron is a clinical stage biopharmaceutical company focused on collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
- Reuters•last month
BRIEF-Geron's Unit To Invest 283.0 Mln Yuan In Stainless Steel Plate Project
July 17 (Reuters) - Geron Co Ltd: * SAYS UNIT TO INVEST 283.0 MILLION YUAN ($42.35 million) IN STAINLESS STEEL PLATE PROJECT Source text in Chinese: https://bit.ly/2uGwvZt Further company coverage: ($1 ...
- Zacks•last month
Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
Investors in Geron (GERN) need to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•last month
These Biotech Companies are a Treat for Investors
HENDERSON, NV / ACCESSWIRE / July 8, 2018 / In order to take a drug to market the cost was estimated to be $2.4 billion. This has caused many biotech firms to enter the device market, rather than drug ...
- Motley Fool•last month
Why Geron Corp. Stock Has Skyrocketed 90.6% in 2018 (So Far)
A key decision on its only drug in development is on tap.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Geron and Celgene
NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...
- Market Realist•2 months ago
Understanding Geron Corp’s IMerge Trial
IMerge, a two-part clinical trial, is evaluating Geron’s (GERN) imetelstat in transfusion-dependent patients with low- or intermediate-risk myelodysplastic syndromes who have relapsed after or are refractory to prior treatment with an erythropoiesis-stimulating agent. Its primary efficacy endpoint is planned to be the rate of RBC-TI (red blood cell transfusion independence) for at least eight weeks. Key secondary endpoints are to be RBC-TI rates for 24 weeks, the amount of and changes in red blood cell transfusions, and hematologic improvement.
- Market Realist•2 months ago
Insights into Geron’s Collaboration with Janssen Biotech
In August 2015, Geron (GERN) entered into a market issuance sales agreement with MLV, under which Geron could issue and sell its common stock for up to $50 million. Under the agreement, in Q1 2018, Geron sold ~776,800 shares of its common stock for net proceeds of ~$1.6 million. Geron entered into a collaboration and licensing agreement with Janssen Biotech in November 2014.
- Market Realist•2 months ago
A Look at Geron’s Imetelstat Research Program
IMbark, a Phase 2 clinical trial, is evaluating two dose levels of Geron’s (GERN) imetelstat in ~200 myelofibrosis patients who have relapsed after or are refractory to prior treatment with a janus kinase inhibitor. The primary endpoints for the trial are the spleen and symptom response rates. The secondary endpoints of the trial include safety and overall survival. Geron expects an overall survival assessment to provide key information for the imetelstat program for potential future clinical trials. The drug’s safety profile was found to be consistent with prior clinical trials focusing on hematologic malignancies.
- Market Realist•2 months ago
Understanding Geron’s Cash Flow and Bottom Line
Its interest expenses fell YoY (year-over-year) to $18,000 from $21,000, and its net loss was stable YoY, growing slightly to ~$7.19 million from $7.18 million. Its net loss per share improved YoY, shrinking to $0.04 from $0.05. In Q1 2018, Geron’s cash outflow from operating activities rose YoY to $7.37 million from $7.31 million. Its current ratio, which measures how effectively it can meet its short-term obligations, improved YoY to 20.8 from 9.
- Market Realist•2 months ago
Analysts’ Ratings for Geron and Peers
In collaboration with Janssen Biotech, biopharmaceutical company Geron (GERN) is currently supporting the clinical development of imetelstat for hematologic myeloid malignancies. Early clinical data for the drug suggests it may have disease-modifying activity by inhibiting progenitor cells of malignant clones for myelofibrosis, myelodysplastic syndromes, and essential thrombocythemia. The sole analyst covering Geron recommends “hold.” In April, there were three analysts covering the stock, of which one recommended “buy,” and two recommended “hold.” Their target price was $5.50.
